U5P logo

Vivani Medical DB:U5P Stock Report

Last Price

€1.14

Market Cap

€67.6m

7D

-1.7%

1Y

34.9%

Updated

20 Nov, 2024

Data

Company Financials +

U5P Stock Overview

A preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. More details

U5P fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vivani Medical, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivani Medical
Historical stock prices
Current Share PriceUS$1.14
52 Week HighUS$5.30
52 Week LowUS$0.74
Beta3.51
11 Month Change2.70%
3 Month Change-1.72%
1 Year Change34.91%
33 Year Changen/a
5 Year Changen/a
Change since IPO-71.85%

Recent News & Updates

Recent updates

Shareholder Returns

U5PDE Medical EquipmentDE Market
7D-1.7%-0.4%-0.4%
1Y34.9%-7.1%7.1%

Return vs Industry: U5P exceeded the German Medical Equipment industry which returned -6.1% over the past year.

Return vs Market: U5P exceeded the German Market which returned 7.8% over the past year.

Price Volatility

Is U5P's price volatile compared to industry and market?
U5P volatility
U5P Average Weekly Movement16.0%
Medical Equipment Industry Average Movement5.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: U5P's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: U5P's weekly volatility has decreased from 45% to 16% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a36Adam Mendelsohnwww.vivani.com

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.

Vivani Medical, Inc. Fundamentals Summary

How do Vivani Medical's earnings and revenue compare to its market cap?
U5P fundamental statistics
Market cap€67.63m
Earnings (TTM)-€22.26m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
U5P income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$23.46m
Earnings-US$23.46m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did U5P perform over the long term?

See historical performance and comparison